Chlorthalidone/Clonidine Discontinuation: What Providers and Prescribers Need to Know in 2026

If patients are presenting with questions about Clorpres or contacting your office because they can't fill their prescription, the answer is unambiguous: Clorpres (clonidine hydrochloride/chlorthalidone) has been permanently discontinued in the United States. All strengths of the brand-name product and any generic equivalents have been discontinued — not due to safety or efficacy concerns, but for commercial reasons.

This guide provides a practical framework for transitioning affected patients, managing rebound hypertension risk, and selecting appropriate alternative regimens. It also covers documentation considerations and how to use real-time pharmacy tools to reduce friction for your patients.

What Was Discontinued and What Remains Available

Discontinued:

Clorpres 0.1 mg/15 mg tablets (clonidine/chlorthalidone)

Clorpres 0.2 mg/15 mg tablets

Clorpres 0.3 mg/15 mg tablets

Any generic fixed-dose combination of clonidine + chlorthalidone

Still available:

Generic clonidine IR tablets (0.1 mg, 0.2 mg, 0.3 mg) — widely available from multiple manufacturers

Generic chlorthalidone tablets (25 mg, 50 mg) — widely available; 2025 ACC/AHA preferred thiazide-like diuretic

Clonidine transdermal patches — available but with intermittently variable supply

Priority Alert: Rebound Hypertension Risk

The most pressing clinical concern in transitioning patients off Clorpres is the black box warning on clonidine regarding abrupt discontinuation. Sudden cessation of clonidine can cause a rapid rise in blood pressure accompanied by nervousness, agitation, headache, and elevated plasma catecholamines. In severe cases, this rebound hypertension can precipitate hypertensive crisis, myocardial infarction, or stroke.

Patients who run out of Clorpres before they can fill a replacement prescription are at real risk. Proactively contact patients currently on Clorpres if possible — especially those who are elderly, have a history of cardiovascular disease, or have poorly controlled baseline blood pressure — to transition them before their supply runs out.

Transition Protocol: Switching to Individual Generics

For most patients, the simplest and safest transition is to prescribe the two individual generic components at equivalent doses:

Clorpres 0.1/15 mg → Clonidine 0.1 mg + Chlorthalidone 25 mg (nearest available standalone strength)

Clorpres 0.2/15 mg → Clonidine 0.2 mg + Chlorthalidone 25 mg

Clorpres 0.3/15 mg → Clonidine 0.3 mg + Chlorthalidone 25 mg

Note that the standalone chlorthalidone is typically available in 25 mg tablets, not 15 mg. For patients who had been specifically titrated to the 15 mg dose, this dose increase warrants clinical consideration — monitor for hypotension, electrolyte changes, and renal function. In some cases, a prescriber may opt to use hydrochlorothiazide 12.5 mg as a closer approximate to the 15 mg chlorthalidone component.

When to Consider a Regimen Change

The Clorpres discontinuation may be an appropriate opportunity to reassess whether clonidine-based therapy is still the best regimen for your patient. Current ACC/AHA guidelines do not list oral clonidine as a first-line antihypertensive agent. The preferred first-line drug classes are:

Thiazide/thiazide-like diuretics (chlorthalidone, HCTZ, indapamide)

ACE inhibitors (lisinopril, ramipril, enalapril)

Angiotensin receptor blockers (losartan, valsartan, telmisartan)

Dihydropyridine calcium channel blockers (amlodipine, nifedipine)

However, there are legitimate reasons some patients remain on clonidine — including resistant hypertension, hyperadrenergic states, opioid withdrawal management, ADHD (off-label), and certain patients with specific comorbidities. Do not switch patients away from clonidine without a careful review of the original indication and clinical context.

38,781+ patients found their medications in stock

38K+

Find Chlorthalidone/Clonidine In Stock Today →

Tapering Protocol if Discontinuing Clonidine Entirely

If you determine this is the right time to transition a patient off clonidine entirely, gradual tapering is essential. The prescribing information recommends reducing the dose by 0.1 mg every 3–7 days. Overlap with the new antihypertensive regimen before completing the taper. Monitor blood pressure closely throughout the transition.

Helping Patients Find Individual Generics in Stock

Both generic clonidine and chlorthalidone are generally available at most US pharmacies in 2026. For patients who encounter local stock issues, medfinder for Providers allows you to check real-time pharmacy-level stock across your patient's area — saving time for both your office and your patients.

Skip the calls, skip the stress.

Find Chlorthalidone/Clonidine In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Documentation Recommendations

When transitioning patients from Clorpres to individual generics, document:

Previous Clorpres dose and frequency

Reason for transition (product discontinuation)

New individual prescriptions written with doses and frequencies

Patient counseling provided regarding clonidine discontinuation risk

Follow-up blood pressure monitoring plan